Discussions

Parkinson's disease (PD) in vitro models provide a controlled environment to study dopaminergic neuron degeneration, α-synuclein aggregation, and neuroinflammation. These models utilize iPSC-derived neurons, midbrain organoids, and primary cultures to replicate disease mechanisms and test therapeutic strategies. Techniques such as CRISPR gene editing, high-content screening, and biomarker analysis enable researchers to explore drug efficacy, mitochondrial dysfunction, and immune interactions. Advancing PD in vitro models enhances precision medicine, supporting innovative treatment development.